TY  - JOUR
AU  - Liebers, Nora
AU  - Boumendil, Ariane
AU  - Finel, Hervé
AU  - Edelmann, Dominic
AU  - Kobbe, Guido
AU  - Baermann, Ben-Niklas
AU  - Serroukh, Yasmina
AU  - Blaise, Didier
AU  - Beelen, Dietrich Wilhelm
AU  - Solano, Carlos
AU  - Itälä-Remes, Maija
AU  - van Meerten, Tom
AU  - Choi, Goda
AU  - Schmidt, Susanne A C
AU  - Kröger, Nicolaus
AU  - Byrne, Jenny
AU  - Tudesq, Jean-Jacques
AU  - Ossami Saidy, Anna
AU  - Nunes, Ana
AU  - Siddiqi, Rubina
AU  - Baro, Elande
AU  - Zheng, Dan
AU  - Kloos, Ioana
AU  - Dreger, Peter
AU  - Sureda, Anna
AU  - Glass, Bertram
AU  - Dietrich, Sascha
TI  - Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
JO  - Blood cancer discovery
VL  - 6
IS  - 3
SN  - 2643-3230
CY  - Philadelphia, PA
PB  - American Association for Cancer Research
M1  - DKFZ-2025-00304
SP  - 182-190
PY  - 2025
N1  - #EA:B340# / 2025 May 5;6(3):182-190
AB  - Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3
LB  - PUB:(DE-HGF)16
C6  - pmid:39913291
DO  - DOI:10.1158/2643-3230.BCD-24-0178
UR  - https://inrepo02.dkfz.de/record/298594
ER  -